Ayush journal of integrative oncology. · 2025 · 30 citations · 28 references
MedicineCancer BiologyOncologyCancer GeneticsMetastasisMolecular OncologyCancer ImmunotherapyMalignant NeoplasmsTargeted Cancer TherapyTargeted TherapyTherapeutic ResistanceTumor BiologyAnticancer Drug ResistanceCancer Gene EditingIntra-tumor HeterogeneityMolecular Drug ResistanceResistance To Targeted TherapyTargeted Therapy DevelopmentTherapeutic FailureTherapeutic Resistance Mechanisms
Abstract Cancer remains one of the leading causes of death globally, with an estimated 10 million deaths attributed to the disease in 2024 alone. Despite advancements in early detection, surgical techniques, and adjuvant therapies, cancer still presents significant therapeutic challenges. These challenges arise from the complexity of the disease, including tumor heterogeneity, drug resistance, and metastasis. Tumors are not a single entity but are composed of diverse cell populations with distinct genetic and phenotypic characteristics complicating treatment and often leading to therapeutic failure. In addition, resistance to therapies and the spread of cancer to distant organs (metastasis) make it difficult to achieve lasting remission, particularly in advanced stages of the disease. Consequently, the search for new strategies and targets in anticancer drug discovery remains a critical focus in medical research. The landscape of cancer treatment is continuously evolving, with novel approaches being explored, such as targeted therapies, immunotherapies, and gene editing technologies. However, overcoming the challenges of cancer’s complexity remains a significant hurdle. This article examines current developments in anticancer drug development, emphasizing new strategies, developing targets, and the continuous difficulties faced by scientists trying to create less harmful and more effective cancer treatments.
28
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
Vancheswaran Gopalakrishnan, Luigi Nezi, Alexandre Reuben et al. · Science · 2017 · 4.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2019 · 3.7K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +14
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Joshua D. Cohen, Lu Li, Yuxuan Wang et al. · Science · 2018 · 2.8K citations
Medicine, Oncology, Cancer Screening +16